The median survival of Evi1+/GFPBCR–ABLtg/− mice in our experiments was 287 days, consistent with the previous report,36 which revealed that Evi1-IRES-GFP allele had no unforeseen effect on CML development. This evidence concerns the gene MECOM and chronic myelogenous leukemia, BCR-ABL1 positive.